Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A Tool to Longitudinally Assess the Secretory Capacity of Myeloma Cells throughout the Course of Disease

Nicholas J. Donato, Hannah Elizabeth Schmikla, James J. Driscoll, Rishil Chopra, Ehsan Malek

Blood (2022) 140 (Supplement 1): 4979–4980.

https://doi.org/10.1182/blood-2022-162522

Published: 2022

Journal Articles

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Luke F. Peterson, Hanshi Sun, Yihong Liu, Harish Potu, Malathi Kandarpa, Monika Ermann, Stephen M. Courtney, Matthew Young, Hollis D. Showalter, Duxin Sun, Andrzej Jakubowiak, Sami N. Malek, Moshe Talpaz, Nicholas J. Donato

Blood (2015) 125 (23): 3588–3597.

https://doi.org/10.1182/blood-2014-10-605584

Published: 2015

Includes: Supplemental data

Journal Articles

Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia

Don L Gibbons, MD, PhD, Sabrina Pricl, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Moshe Talpaz, MD, Jorge E. Cortes, MD, Nicholas J. Donato, PhD, Alfonso Quintas-Cardama, MD

Blood (2013) 122 (21): 853.

https://doi.org/10.1182/blood.V122.21.853.853

Published: 2013

Journal Articles

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Luke F. Peterson, PhD, Hanshi Sun, PhD, Yihong Liu, PhD, Malathi Kandarpa, PhD, Diane Giannola, Jessica Mercer, PhD, Hollis D. Showalter, Ph.D., Andrzej Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas J. Donato, PhD

Blood (2012) 120 (21): 2936.

https://doi.org/10.1182/blood.V120.21.2936.2936

Published: 2012

Journal Articles

Antileukemic effects of AMPK activators on BCR-ABL–expressing cells

Eliza Vakana, Jessica K. Altman, Heather Glaser, Nicholas J. Donato, Leonidas C. Platanias

Blood (2011) 118 (24): 6399–6402.

https://doi.org/10.1182/blood-2011-01-332783

Published: 2011

Includes: Supplemental data

Journal Articles

Imatinib is receptive to a collaboration

Nicholas J. Donato

Blood (2011) 118 (15): 4009–4010.

https://doi.org/10.1182/blood-2011-08-373290

Published: 2011

Journal Articles

Bcr-Abl adds another twist to cell fate

Nicholas J. Donato

Blood (2011) 118 (10): 2646–2647.

https://doi.org/10.1182/blood-2011-07-366153

Published: 2011

Journal Articles

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

Hanshi Sun, Vaibhav Kapuria, Luke F. Peterson, Dexing Fang, William G. Bornmann, Geoffrey Bartholomeusz, Moshe Talpaz, Nicholas J. Donato

Blood (2011) 117 (11): 3151–3162.

https://doi.org/10.1182/blood-2010-03-276477

Published: 2011

Includes: Supplemental data

Journal Articles

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Nicholas J Donato, Ph.D., Hanshi Sun, Ph.D., Vaibhav Kapuria, Luke F Peterson, PhD, Geoffrey Bartholomeusz, Ph.D., William G. Bornmann, Ph.D., Moshe Talpaz, M.D.

Blood (2009) 114 (22): 3303.

https://doi.org/10.1182/blood.V114.22.3303.3303

Published: 2009

Journal Articles

Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130.

Vaibhav Kapuria, Luke F Peterson, PhD, William Bornmann, Ph.D., Moshe Talpaz, MD, Nicholas J Donato

Blood (2009) 114 (22): 2907.

https://doi.org/10.1182/blood.V114.22.2907.2907

Published: 2009

Journal Articles

De-Ubiquitinase Inhibition by WP1130 Induces Formation of Aggresomes, Engages Autophagy and Activates Apoptosis in B-Cell Malignancies.

Vaibhav Kapuria, Luke F Peterson, PhD, Moshe Talpaz, MD, Nicholas J Donato

Blood (2009) 114 (22): 3769.

https://doi.org/10.1182/blood.V114.22.3769.3769

Published: 2009

Journal Articles

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

Ji Wu, Feng Meng, Henry Lu, Ling Kong, William Bornmann, Zhenghong Peng, Moshe Talpaz, Nicholas J. Donato

Blood (2008) 111 (7): 3821–3829.

https://doi.org/10.1182/blood-2007-08-109330

Published: 2008

Journal Articles

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

Geoffrey A. Bartholomeusz, Moshe Talpaz, Vaibhav Kapuria, Ling Yuan Kong, Shimei Wang, Zeev Estrov, Waldemar Priebe, Ji Wu, Nicholas J. Donato

Blood (2007) 109 (8): 3470–3478.

https://doi.org/10.1182/blood-2006-02-005579

Published: 2007

Journal Articles

Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in “Classic” and “Blastoid-Variant” Mantle Cell Lymphoma.

Lan V. Pham, PhD, Archito T. Tamayo, Linda C. Yoshimura, Waldeman Priebe, Ph.D, Nicholas J. Donato, Ph.D, Moshe Talpaz, MD, Richard J. Ford, MD, Ph.D

Blood (2006) 108 (11): 2512.

https://doi.org/10.1182/blood.V108.11.2512.2512

Published: 2006

Journal Articles

Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism.

Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, Ph.D., William Bornmann, Ph.D., Ling Y. Kong, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, Ph.D.

Blood (2006) 108 (11): 3423.

https://doi.org/10.1182/blood.V108.11.3423.3423

Published: 2006

Journal Articles

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Nicholas J. Donato, PhD, Ji Wu, M.D., William Bornmann, Ph.D., Moshe Talpaz, M.D.

Blood (2006) 108 (11): 4819.

https://doi.org/10.1182/blood.V108.11.4819.4819

Published: 2006

Journal Articles

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Ji Wu, MD, Feng Meng, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, PhD

Blood (2006) 108 (11): 2132.

https://doi.org/10.1182/blood.V108.11.2132.2132

Published: 2006

Journal Articles

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Ling-Yuan Kong, MD, PhD, Vaibhav Kapuria, Geoffrey Bartholomeusz, PhD, Moshe Talpaz, MD, Waldemar Priebe, PhD, Nicholas J. Donato, PhD

Blood (2005) 106 (11): 1489.

https://doi.org/10.1182/blood.V106.11.1489.1489

Published: 2005

Journal Articles

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling-Yuan Kong, MD, PhD, Feng Meng, MD, Francis Lee, PhD, Moshe Talpaz, MD

Blood (2005) 106 (11): 1087.

https://doi.org/10.1182/blood.V106.11.1087.1087

Published: 2005

Journal Articles

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling Y. Kong, MD, PhD, Feng Meng, MD, Waldemar Priebe, PhD, Moshe Talpaz, MD

Blood (2004) 104 (11): 2964.

https://doi.org/10.1182/blood.V104.11.2964.2964

Published: 2004

NARROW

A Tool to Longitudinally Assess the Secretory Capacity of Myeloma Cells throughout the Course of Disease

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia

Usp9x Silencing and Enzyme Inhibition Suppress Myeloma Cell Survival and in Vivo Tumor Growth.

Antileukemic effects of AMPK activators on BCR-ABL–expressing cells

Imatinib is receptive to a collaboration

Bcr-Abl adds another twist to cell fate

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130.

De-Ubiquitinase Inhibition by WP1130 Induces Formation of Aggresomes, Engages Autophagy and Activates Apoptosis in B-Cell Malignancies.

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in “Classic” and “Blastoid-Variant” Mantle Cell Lymphoma.

Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism.

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only